Efficiency of using Canephron® N in the treatment of children with secondary hyperoxaluria

T.P. Borysova


Background. The purpose of our work was to study the clinical effectiveness of the application of phytotherapeutic drug Canephron® N for secondary hyperoxaluria in children in combination with diet as compared to the dietary treatment alone. Materials and methods. 46 children aged 6–18 years with secondary hyperoxaluria were examined. Depending on the treatment scheme, patients are divided into groups: the main group (23 children) and the comparison group (23 persons). All children received dietary treatment with the exception of high-oxalic acid foods and sufficient drinking regime. In addition to diet therapy, the patients of the main group were treated with Canephron® N for 3 months. Daily excretion of oxalates, calcium, uric acid, phosphate and calcium/creatinine ratio in the morning urine before treatment and after 3 months of therapy were studied. Results. After 3 months of therapy, there was a decrease in daily excretion of oxalate in urine in both observation groups. The decrease in urinary excretion of oxalate on the background of therapy was more significant in children of the main group than in the comparison group (3.050 ± 0.320 vs. 1.600 ± 0.102, p < 0.001). The incidence of hyperoxaluria on the background of therapy in the main group decreased from 100 to 56.5 % (p < 0.01), in the comparison group it almost did not change (from 100 to 82.6 %, p > 0.05). The incidence of hypercalciuria in both groups did not change. At the same time, the daily excretion of calcium, phosphorus and uric acid in the main group was significantly reduced. In patients of the main group, there was a decrease in the erythrocyturia rate — from 52.2 to 17.4 % (p < 0.01). In patients of the comparison group, this indicator did not change significantly. The level of daily proteinuria before and after the treatment decreased only in children of the main group — from 0.117 g/day to 0.052 g/day (p < 0.02). Conclusions. Using phytotherapeutic drug Canephron® N for three-month therapy of secondary hyperoxaluria in children in combination with dietary treatment is more effective than monotherapy with diet and leads to a 3-time decrease of the oxalate level in urine. Treatment with restriction of high-oxa­lic acid foods gives the result of not more than 1.6 times. The inclusion of phytotherapeutic drug Canephron® N is accompanied by a 3-fold decrease in the erythrocyturia rate and a reduction of daily proteinuria.


hyperoxaluria; children; treatment


Averyanova NI, Balueva LG. Oksalatic crystalluria in children. Mezhdunarodnyi zhurnal prikladnykh i fundamental'nykh issledovanii. 2012;5:25-27. (in Russian).

Bagdasarova IV, Stoeva TV, Zheltovskaia N.I. Examination of clinical and laboratorial features at dysmetabolic nephropathies at children. Perinatologiya i pediatriya.2009;39(3):71-73. (in Russian).

Dlin VV, Ignatova MS, Morozov SL, Yuryeva EA, Osmanov IM. Dysmetabolic nephropathy in children. Rossiyskiy Vestnik Perinatologii i Pediatrii. 2012;57(5):36-44. (in Russian).

Dlin VV, Osmanov IM. Dysmetabolic nephropathy with calcium oxalate crystalluria. Effektivnaia farmakoterapiia. 2013;42:8-17. (in Russian).

Zhigunova AK. Comprehensive treatment of dysmetabolic nephropathies. The role of herbal medicine. Ukrainian Medical Journal. 2013;4:37-44. (in Russian).

Zubarenko AV, Stoeva TV. Dysmetabolic nephropathy in pediatric practice. Message 1. Principles of diagnostics. Zdorov'ye Rebenka. 2009;4(19):132-136. (in Russian).

Kirillov VI, Bogdanova NA. Clinico-pathogenetic justification of the effectiveness of the herbal preparation Сanephron H in nephrology of childhood. Russkii meditsinskii zhurnal. 2015;23(28):1710-1714. (in Russian).

Kazakova KYe, Kondrat'yeva YeI, Terent'eva AA, Sukhanova GA. Rehabilitation of children with dismetabolic nephropathies, living in industrial cities. Voprosy Sovremennoi Pediatrii. 2009;8(1):41-45. (in Russian).

Voronina NV, Gribovskaya NV, Yevseev AN, Ezerskiy DV. The urinary syndrome features in patient with oxalate nephropathy compared to the results of kidney biopsy. Dal'nevostochnyi meditsinskii zhurnal. 2013;3:15-19. (in Russian).

Popp M. 2013. Evidence-based phitotherapy in everyday pediatric practice. Effektivnaia farmakoterapiia. 2013;14(2):48-51. (in Russian).

Türk C, Knoll T, Petrik A, et al. Guidelines on Urolithiasis European Association of Urology 2013. Pochki. 2013;4(06):44-54. (in Russian).

Stepanova N. Hyperoxaluria: mechanisms of formation and consequences. Ukrai'ns'kyj zhurnal nefrologii' ta dializu. 2016;3(51):55-66. (in Russian).

Sukalo AV, Shevchenko OS. The use of the drug Сanephron H for dismetabolic nephropathy in children. Prescription. 2009;1(63):106-110. (in Russian).

Dlin VV, Shatokhina OV, Osmanov IM, Yuryeva EA. Effectiveness of Сanephron ® H in children with dysmetabolic nephropathy with oxalate-calcium crystalluria. Vestnik pediatricheskoy farmacologii i nutritsiologii. 2008;4(5):66-69. (in Russian).

Naber KG. Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. Res Rep Urol. 2013;5:39-46. doi: 10.2147/RRU.S39288.

Nicoletta JA, Lande MB. Medical evaluation and treatment of urolithiasis. Pediatr Clin North Am. 2006 Jun;53(3):479-91, vii. doi: 10.1016/j.pcl.2006.03.001.

Strohmaier WL. Recent advances in understanding and managing urolithiasis. F1000Res. 2016 Nov 8;5:2651. doi: 10.12688/f1000research.9570.1.

Copyright (c) 2017 Zdorov'ye Rebenka - Child`s Health

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2019


   Seo анализ сайта